Provided by Tiger Trade Technology Pte. Ltd.

Verastem

7.90
-0.1500-1.86%
Post-market: 7.900.00000.00%19:30 EDT
Volume:1.76M
Turnover:13.99M
Market Cap:715.45M
PE:-3.27
High:8.18
Open:8.00
Low:7.74
Close:8.05
52wk High:10.82
52wk Low:3.43
Shares:90.56M
Float Shares:70.57M
Volume Ratio:1.05
T/O Rate:2.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4143
EPS(LYR):-3.0223
ROE:-471.16%
ROA:-49.59%
PB:14.31
PE(LYR):-2.61

Loading ...

Verastem Q2 Revenue Jumps on New Product Sales and Milestone

Reuters
·
Aug 07

Verastem Q2 FY26 GAAP Net Loss Widens to $34.67 Million; Revenue Rises to $40.08 Million

Reuters
·
Aug 07

Verastem Q2 Adj. EPS $(0.35) Beats $(0.43) Estimate, Sales $25.078M Beat $23.093M Estimate

Benzinga Earnings
·
Aug 07

Verastem Q2 Operating Expenses USD 72.788 Million

Reuters
·
Aug 07

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

THOMSON REUTERS
·
Aug 07

Verastem’s TARGET-D 202 Trial Puts Fresh Focus on KRAS G12D Lung Cancer

TIPRANKS
·
Jul 31

Verastem Oncology Doses First Patient in Target-D 203 Phase 2 Registration-Directed Trial of Vs-7375 Oral Kras G12d (on/off) Inhibitor for Kras G12d-Mutated Metastatic Colorectal Cancer

THOMSON REUTERS
·
Jul 29

Verastem - Initiates Treatment in All Three Target-D Phase 2 Trials

THOMSON REUTERS
·
Jul 29

Press Release: Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026

Dow Jones
·
Jul 23

Verastem Oncology to Report Q2 2026 Financial Results in Conference Call

Reuters
·
Jul 23

Verastem doses first patient in TARGET-D 202 Phase 2 trial

TIPRANKS
·
Jul 23

Verastem Oncology Doses First Patient in Target-d 202 Phase 2 Registration-directed Trial of Vs-7375 for Kras G12d-mutated Advanced Non-small Cell Lung Cancer

THOMSON REUTERS
·
Jul 23

These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why

Benzinga_recent_news
·
Jul 22

Verastem’s KRAS G12D Trial Targets a New Niche in Colorectal Cancer

TIPRANKS
·
Jul 18

Verastem is Maintained at Outperform by RBC Capital

Dow Jones
·
Jul 08

RBC Capital Adjusts Verastem Price Target to $14 From $15, Maintains Outperform Rating

MT Newswires Live
·
Jul 07

Verastem Oncology Grants 399,750 Rsus, Sets New-hire Stock Option Exercise Price at $4.1

Reuters
·
Jul 03

Verastem Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 03

Verastem is Maintained at Buy by BTIG

Dow Jones
·
Jul 03

Cardiff, Verastem, Fluence, Quantum-Si, Opera Insider Shock

TIPRANKS
·
Jun 27